Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2012-07, Vol.77 (1), p.31-37
• Main Authors: Basseres, Daniela S, D’Alò, Francesco, Yeap, Beow Y, Löwenberg, Ester C, Gonzalez, David A, Yasuda, Hiroyuki, Dayaram, Tajhal, Kocher, Olivier N, Godleski, John J, Richards, William G, Meyerson, Matthew, Kobayashi, Susumu, Tenen, Daniel G, Halmos, Balázs, Costa, Daniel B
• Format: Article
• Language: English
• Subjects: Adenocarcinoma; Adenocarcinoma - genetics; Adenocarcinoma - metabolism; Adenocarcinoma - mortality; Adenocarcinoma - pathology; Biological and medical sciences; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - mortality; Carcinoma, Non-Small-Cell Lung - pathology; Cell Line, Tumor; DNA Methylation; DNA Mutational Analysis; Down-Regulation; Downregulation; Epigenesis, Genetic; Epigenetic; Female; Foxa2; Gene Dosage; Gene Expression; Gene Expression Regulation, Neoplastic; Hematology, Oncology and Palliative Medicine; Hepatocyte Nuclear Factor 3-beta - genetics; Hepatocyte Nuclear Factor 3-beta - metabolism; Humans; Kaplan-Meier Estimate; Lung cancer; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - mortality; Lung Neoplasms - pathology; Male; Medical sciences; Methylation; Middle Aged; Mutation; Non-small-cell lung cancer; Pneumology; Prognosis; Promoter Regions, Genetic; Pulmonary/Respiratory; Transcription factors; Tumors; Tumors of the respiratory system and mediastinum
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2012.01.011

Abstract Purpose We sought to determine the mechanisms of downregulation of the airway transcription factor Foxa2 in lung cancer and the expression status of Foxa2 in non-small-cell lung cancer (NSCLC). Methods A series of 25 lung cancer cell lines were evaluated for Foxa2 protein expression, FOXA2 mRNA levels, FOXA2 mutations, FOXA2 copy number changes and for evidence of FOXA2 promoter hypermethylation. In addition, 32 NSCLCs were sequenced for FOXA2 mutations and 173 primary NSCLC tumors evaluated for Foxa2 expression using an immunohistochemical assay. Results Out of the 25 cell lines, 13 (52%) had undetectable FOXA2 mRNA. The expression of FOXA2 mRNA and Foxa2 protein were congruent in 19/22 cells ( p = 0.001). FOXA2 mutations were not identified in primary NSCLCs and were infrequent in cell lines. Focal or broad chromosomal deletions involving FOXA2 were not present. The promoter region of FOXA2 had evidence of hypermethylation, with an inverse correlation between FOXA2 mRNA expression and presence of CpG dinucleotide methylation ( p < 0.0001). In primary NSCLC tumor specimens, there was a high frequency of either absence (42/173, 24.2%) or no/low expression (96/173, 55.4%) of Foxa2. In 130 patients with stage I NSCLC there was a trend towards decreased survival in tumors with no/low expression of Foxa2 (HR of 1.6, 95%CI 0.9–3.1; p = 0.122). Conclusions Loss of expression of Foxa2 is frequent in lung cancer cell lines and NSCLCs. The main mechanism of downregulation of Foxa2 is epigenetic silencing through promoter hypermethylation. Further elucidation of the involvement of Foxa2 and other airway transcription factors in the pathogenesis of lung cancer may identify novel therapeutic targets.